Abstract
Background: CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is a chemokine that has a role in the development of cardiovascular and other diseases. We have previously scanned the full length CXCL5 gene and reported the -156G>C (rs352046) polymorphism in the promoter region of this gene.
Objective: The aim of this study was to examine whether there was an association between this polymorphism and type 2 diabetes mellitus or its microvascular complications in an Iranian population.
Methods: A total of 230 patients with type 2 diabetes were recruited from Rafsanjan, in the south-east of Iran; 102 healthy control subjects were recruited from the same area. The region containing the CXCL5 -156G>C polymorphism was genotyped by PCR amplification and restriction fragment length polymorphism analysis, and allele frequency data were analyzed using STATA 8 software.
Results: We observed that patients with type 2 diabetes had a higher frequency of carrying either the G/C or C/C genotype compared with healthy controls (C/G + C/C vs G/G; p = 0.004; odds ratio [OR] 2.17; 95% CI 1.27, 3.80). In addition, the frequency of allele C was significantly increased in patients with diabetes compared with controls (p = 0.01; OR 1.72; 95% CI 1.07, 2.86). No association was found between this polymorphism and diabetic microvascular complications.
Conclusions: Our findings suggest a role of CXCL5 in the pathogenesis of diabetes. The mechanism behind this role needs to be investigated further. Moreover, replications in other populations with larger sample sizes are required to confirm these findings.
This is a preview of subscription content, log in via an institution to check access.
References
Walz A, Burgener R, Car B, et al. Nucleotide structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174: 1355–62
Imaizumi T, Albertine KH, Jicha DL, et al. Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 1997; 17: 181–92
Saurer L, Reber P, Schaffner T, et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterology 2000; 118: 356–67
Shokuhi S, Bhatia M, Christmas S, et al. Levels of the chemokines growth-related oncogene alpha and epithelial neutrophil-activating protein 78 are raised in patients with severe acute pancreatitis. Br J Surg 2002; 89: 566–72
Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012–8
Walz A, Schmutz P, Mueller C, et al. Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease. J Leukoc Biol 1997; 62: 604–11
Zineh I, Luo X, Welder GJ, et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 2006 Mar; 26(3): 333–40
Chang MS, McNinch J, Basu R, et al. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem 1994; 269: 25277–82
Amoli MM, Larijani B, Thomson W, et al. Two polymorphisms in the epithelial cell-derived neutrophil-activating peptide (ENA-78) gene. Dis Markers 2005; 21(2): 75–7
Zineh I, Welder GJ, Langaee TY. Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene. Clin Chim Acta 2006 Aug; 370(1-2): 72–5
Amoli MM, Ollier WE, Gonzalez-Gay MA. Lack of association of epithelial cell-derived neutrophil-activating peptide (ENA)-78 gene polymorphism with susceptibility to biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2007 Jan2 -Feb; 25(1 Suppl. 44): S40
DCCT Research Group. Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988 Apr; 37(4): 476–81
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26Suppl.l: S5–20
Zineh I, Aquilante CL, Langaee TY, et al. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 2006 Mar 7; 33(5): 258–63
Acknowledgments
Dr Zineh and the University of Florida have filed a US patent application (#20080045582) for using CXCL5 polymorphism and ENA-78 protein concentrations as diagnostic and prognostic tools. No ruling has yet been made.
The other authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ranjbar, S.H., Amiri, P., Zineh, I. et al. CXCL5 Gene Polymorphism Association with Diabetes Mellitus. Mol Diag Ther 12, 391–394 (2008). https://doi.org/10.1007/BF03256304
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256304